FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression.

PubWeight™: 2.50‹?› | Rank: Top 2%

🔗 View Article (PMC 2954624)

Published in Transplantation on March 27, 1994


M L Jordan1, R Shapiro, C A Vivas, V P Scantlebury, P Rhandhawa, G Carrieri, J McCauley, A J Demetris, A Tzakis, J J Fung

Author Affiliations

1: Division of Urologic Surgery and Renal Transplantation, University of Pittsburgh Medical Center, Pennsylvania 15213.

Articles citing this

Tacrolimus in pediatric renal transplantation. Transplantation (1996) 1.18

A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. Transplant Proc (1995) 1.13

FK506 in pediatric kidney transplantation--primary and rescue experience. Pediatr Nephrol (1995) 1.11

Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy. Ann Surg (1996) 0.98

Tacrolimus rescue therapy for renal allograft rejection--five-year experience. Transplantation (1997) 0.95

Tacrolimus (FK506)-Associated Renal Pathology. Adv Anat Pathol (1997) 0.90

Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. Clin Transplant (1997) 0.90

The superiority of tacrolimus in renal transplant recipients -- the Pittsburgh experience. Clin Transpl (1995) 0.85

A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg (1996) 0.83

Tacrolimus for rescue of refractory renal allograft rejection. Transplant Proc (1998) 0.81

Long-term results of pancreas transplantation under tacrolius immunosuppression. Transplantation (1999) 0.80

Long-term follow-up of tacrolimus rescue therapy for renal allograft rejection. Transplant Proc (1997) 0.79

Outcome of tacrolimus conversion therapy for renal allograft rejection: 5-year follow-up. Transplant Proc (1999) 0.78

Renal transplantation at the University of Pittsburgh: the impact of FK506. Clin Transpl (1994) 0.78

Cadaveric renal transplantation against a positive historic crossmatch under tacrolimus immunosuppression: long-term follow-up. Transplant Proc (1997) 0.76

Tacrolimus rescue therapy for renal transplant rejection. Transplant Proc (1996) 0.75

Five-year experience with tacrolimus rescue for renal allograft rejection. Transplant Proc (1997) 0.75

Islet cell transplantation. J R Soc Med (2002) 0.75

Maintenance pharmacological immunosuppressive strategies in renal transplantation. Postgrad Med J (1997) 0.75

Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction. J Heart Lung Transplant (1997) 0.75

Articles cited by this

A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc (1987) 8.45

Kidney transplantation under FK 506. JAMA (1990) 7.45

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29

RS-61443--a phase I clinical trial and pilot rescue study. Transplantation (1992) 1.97

RS-61443--a new, potent immunosuppressive agent. Transplantation (1991) 1.57

Analyses of the UNOS Scientific Renal Transplant Registry at three years--early events affecting transplant success. Transplantation (1992) 1.37

FK 506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc (1991) 1.37

Sequential antilymphoblast globulin and cyclosporine for renal transplantation. Transplantation (1987) 1.16

A randomized prospective trial comparing cyclosporine monotherapy with triple-drug therapy in renal transplantation. Transplantation (1991) 1.07

Sequential therapy--a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. Transplantation (1992) 1.05

A dual mechanism of immunosuppression by FK-506. Differential suppression of IL-4 and IL-10 levels in T helper 2 cells. Transplantation (1993) 1.05

Withdrawal of steroids after renal transplantation--clinical predictors of outcome. Transplantation (1992) 1.01

15-Deoxyspergualin for induction of graft nonreactivity after cardiac and renal allotransplantation in primates. Transplantation (1990) 0.96

Sequential antilymphocyte globulin/cyclosporine immunosuppression in cadaveric renal transplantation. Effect of duration of ALG therapy. Transplantation (1989) 0.94

Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. Transplant Proc (1990) 0.93

Transplantation of pediatric en bloc kidneys under FK 506 immunosuppression. Transplant Proc (1991) 0.89

Treatment of renal transplant rejection with 15-deoxyspergualin--a dose-finding study in man. Transplant Proc (1992) 0.88

Articles by these authors

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24

The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Kidney transplantation under FK 506. JAMA (1990) 7.45

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78

Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54

Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

Liver transplantation (1). N Engl J Med (1989) 4.53

Nucleic acid reactivity and conformation. II. Reaction of cytosine and uracil with sodium bisulfite. J Biol Chem (1973) 4.44

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92

X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet (2001) 3.86

Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85

The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med (2001) 3.85

Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Transplantation of multiple abdominal viscera. JAMA (1989) 3.59

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55

Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43

The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant (2011) 3.42

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13

Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc (1987) 3.11

A multifactorial system for equitable selection of cadaver kidney recipients. JAMA (1987) 3.01

Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98

Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95

Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95

Liver transplantation (2). N Engl J Med (1989) 2.93

Deamination of cytosine derivatives by bisulfite. Mechanism of the reaction. J Am Chem Soc (1974) 2.92

Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res (1997) 2.91

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

Equitable allocation of extrarenal organs: with special reference to the liver. Transplant Proc (1988) 2.85

Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84

The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81

Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81

Interaction of the influenza virus nucleoprotein with the cellular CRM1-mediated nuclear export pathway. J Virol (2001) 2.76

Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75

The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med (1995) 2.68

Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66

Medical education and health for all. Aust J Public Health (1995) 2.65

A review of adult and pediatric post-transplant liver pathology. Pathol Annu (1987) 2.62

Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62

Mitochondrial DNA inherited variants are associated with successful aging and longevity in humans. FASEB J (1999) 2.61

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57

Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol (2013) 2.51

Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50

A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49

Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48

Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant (2006) 2.48

Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med (1994) 2.48

Liver transplantation across ABO blood groups. Surgery (1986) 2.39

Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38

The antibody crossmatch in liver transplantation. Surgery (1986) 2.33

The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32